PegBio Co., Ltd. (HKG:2565)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
6.24
+0.04 (0.65%)
Jun 18, 2026, 2:15 PM HKT
Market Cap2.42B -45.7%
Revenue (ttm)n/a
Net Income-231.87M
EPS-0.61
Shares Out 391.09M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume15,428,450
Open6.24
Previous Close6.20
Day's Range6.10 - 6.59
52-Week Range6.06 - 77.00
Betan/a
AnalystsStrong Buy
Price Target101.80 (+1,531.41%)
Earnings DateAug 26, 2026

About PegBio

PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company’s PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 an Opioid receptor antagonist, which is in phase II clinical trials for the treatment ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 58
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2565
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements